Claims for Patent: 10,047,033

Summary for Patent: 10,047,033

Title:	Compositions comprising oxo-derivatives of fatty acids and methods of making and using same
Abstract:	The present disclosure provides 15-oxo-EPA and 15-oxo-DGLA, compositions comprising 15-oxo-EPA and/or 15-oxo-DGLA, and methods of treating and/or preventing fibrosis, skin disorders, inflammation, kidney disease or renal dysfunction in a subject in need thereof by administering 15-oxo-EPA and/or 15-oxo-DGLA.
Inventor(s):	Manku; Mehar (Birmingham, GB), Climax; John (Dublin, IE), Coughlan; David (Dublin, IE)
Assignee:	DS BIOPHARMA LIMITED (Dublin, IE)
Application Number:	15/153,476
Patent Claims:	1. A method of treating liver fibrosis in a subject in need thereof, the method comprising administering to the subject (5Z,8Z,11Z,13E,17Z)-15-oxoicosa-5,8,11,13, 17-pentaenoic acid and/or (8Z,11Z,13E)-15-oxoicosa-8,11,13-trienoic acid. 2. The method of claim 1, wherein the fibrosis is associated with non-alcoholic fatty liver disease (NAFLD). 3. The method of claim 1, wherein a NAFLD activity score (NAS) is reduced in the subject after administration of the composition, optionally: wherein the NAS is reduced in the subject compared to baseline, or wherein the subject is on fibrosis therapy and the NAS is reduced in the subject in comparison to a second subject who has not been administered the composition, wherein the second subject optionally has been administered a placebo, and/or wherein the second subject is optionally on fibrosis therapy, and optionally wherein the fibrosis therapy is continued during administration of the compound, composition, or pharmaceutical composition. 4. The method of claim 3, wherein the fibrosis therapy comprises administration of an angiotensin II receptor blocker (ARB) selected from the group consisting of: valsartan, telmisartan, losartan, irbesartan, azilsartan, eprosartan, olmesartan, or a combination of any of the foregoing. 5. The method of claim 1, wherein the (5Z,8Z,11Z,13E,17Z)-15-oxoicosa-5,8,11,13,17-pentaenoic acid and/or the (8Z,11Z,13E)-15-oxoicosa-8,11,13-trienoic acid is orally administered. 6. The method of claim 1, wherein the 5Z,8Z,11Z,13E,17Z)-15-oxoicosa-5,8,11,13,17-pentaenoic acid or the (8Z,11Z,13E)-15-oxoicosa-8,11,13-trienoic acid is the only active ingredient in the composition. 7. The method of claim 3, wherein the composition further comprises an additional agent for affecting the fibrosis therapy. 8. The method of claim 1 further comprising identifying the subject as having fibrosis before administering the 5Z,8Z,11Z,13E,17Z)-15-oxoicosa-5,8,11,13,17-pentaenoic acid, the composition comprising 5Z,8Z,11Z,13E,17Z)-15-oxoicosa-5,8,11,13,17-pentaenoic acid and/or (8Z,11Z,13E)-15-oxoicosa-8,11,13-trienoic acid. 9. The method of claim 1 further comprising identifying the subject as having an increased risk of developing fibrosis before administering the 5Z,8Z,11Z,13E,17Z)-15-oxoicosa-5,8,11,13,17-pentaenoic acid and/or the (8Z,11Z,13E)-15-oxoicosa-8,11,13-trienoic acid. 10. The method of claim 8, wherein the step of identifying comprises determining a NAS associated with the subject, optionally wherein the NAS associated with the subject is at least 3. 11. The method of claim 8, wherein the step of identifying comprises screening for a genetic mutation in a nucleic acid molecule associated with the subject. 12. The method of claim 8, wherein the step of identifying comprises obtaining an analysis of blood and/or serum associated with the subject. 13. The method of claim 8, wherein the step of identifying comprises examining a tissue associated with the subject, optionally wherein the tissue is a histological tissue sample associated with the subject. 14. The method of claim 10 further comprising determining a second, lower NAS value associated with the subject after administering the composition for a period of time. 15. The method of claim 1 wherein the 5Z,8Z,11Z,13E,17Z)-15-oxoicosa-5,8,11,13,17-pentaenoic acid or the (8Z,11Z,13E)-15-oxoicosa-8,11,13-trienoic acid is in free acid form. 16. The method of claim 1 wherein the 5Z,8Z,11Z,13E,17Z)-15-oxoicosa-5,8,11,13,17-pentaenoic acid or the (8Z,11Z,13E)-15-oxoicosa-8,11,13-trienoic acid is in esterified form. 17. The method of claim 1 wherein the 5Z,8Z,11Z,13E,17Z)-15-oxoicosa-5,8,11,13,17-pentaenoic acid or the (8Z,11Z,13E)-15-oxoicosa-8,11,13-trienoic acid is in ethyl ester form. 18. The method of claim 3, wherein the fibrosis therapy comprises administration of a hepatitis C virus (HCV) non-antiviral agent, an HCV antiviral agent, a hepatitis B virus (HBV) non-antiviral agent, an HBV antiviral agent, a primary biliary cirrhosis agent, an alcoholic hepatitis agent, a primary sclerosing cholangitis agent, a NASH agent, an autoimmune hepatitis agent, a pulmonary fibrosis agent, a cystic fibrosis agent, a renal fibrosis agent, a skin fibrosis agent, a myelofibrosis agent, an eosinophilic esophagitis agent, an anti-TGF-.beta. agent, an anti-CTGF agent, a recombinant human serum amyloid P agent, an anti-IL-4 agent, an anti-IL-5 agent (e.g., mepolizumab), an anti-IL-13 agent, a neurochemical receptor agent, an anti-IL-17A agent, a Hh or Hh(R) SMO antagonist, a CCR5 antagonist, a CCR4 cell recruitment inhibitor, a CXCR4 antagonist, an anti-CXCR4 agent, a CXCR3 antagonist, an anti-CCL17 agent, a NOX inhibitor, copaxone, adiponectin, an AMPK agonist, Y-box binding protein-1, a myofibroblast recruitment inhibitor, an anti-Th17 MMP inducer, an anti-extracellular matrix deposition compound, an adenosine receptor antagonist, a micro-RNA (miR) agent, a stem cell, tenofovir, an anti-collagen crosslinking agent (e.g., simtuzumab, mogamulizumab), or a combination of any of the foregoing. 19. The method of claim 16, wherein the esterified form is an alkyl ester form or a triglyceride form.

Details for Patent 10,047,033

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Glaxosmithkline Llc	NUCALA	mepolizumab	For Injection	125526	November 04, 2015	10,047,033	2035-05-13
Glaxosmithkline Llc	NUCALA	mepolizumab	Injection	125526	June 06, 2019	10,047,033	2035-05-13
Glaxosmithkline Llc	NUCALA	mepolizumab	Injection	125526	January 22, 2022	10,047,033	2035-05-13
Glaxosmithkline Llc	NUCALA	mepolizumab	For Injection	761122	June 06, 2019	10,047,033	2035-05-13